瘧疾疫苗市場報告：2030 年趨勢、預測與競爭分析

瘧疾疫苗趨勢與預測

預計到 2030 年，全球瘧疾疫苗市場將達到 69 億美元，2024 年至 2030 年複合年成長率為 18.6%。該市場的主要驅動力是對瘧疾疫苗的需求不斷成長、前紅血球生成疫苗的出現以及對疫苗輸送平台的日益偏好。全球瘧疾疫苗市場的未來看起來充滿希望，醫院、專科診所和居家醫療市場都有機遇。

Lucintel 預測，溶血前疫苗預計將在預測期內達到最高成長。

在這個市場中，預計醫院將在預測期內實現最高成長。

由於擁有強大的醫療基礎設施、疫苗研發的高投資以及主要製造商的存在，北美仍然是最大的地區。

瘧疾疫苗市場新趨勢

瘧疾疫苗市場出現了一些新興趨勢，這些趨勢將塑造瘧疾預防和控制的未來。這些趨勢源於技術的進步、國際合作的加強以及對公共衛生的日益重視。以下的摘要概述了影響市場的關鍵促進因素。

• 全球合作加強：國際夥伴關係變得更加頻繁，使得各國之間能夠交流研究、資源和專業知識。這一趨勢正在導致更有效、更容易獲得的瘧疾疫苗的開發。已開發國家和開發中國家之間的合作對於應對瘧疾流行地區面臨的獨特挑戰尤其重要，從而製定更有針對性和永續的疫苗解決方案。
• 下一代疫苗：目前許多研究都集中在下一代瘧疾疫苗上，該疫苗可以廣泛預防多種寄生蟲菌株。這些疫苗旨在解決困擾當前疫苗的局限性，例如功效低下和病毒株特異性保護。這一趨勢對於長期控制和根除瘧疾極為重要，因為它考慮到了瘧疾原蟲隨時間的變化以及對現有藥物的抗藥性。
• 疫苗的可近性 人們越來越致力於確保瘧疾疫苗對於流行地區的居民來說是有效且負擔得起的。這項進展反映出人們認知到解決疫苗分發挑戰對於實現全球消除瘧疾目標至關重要。這包括降低製造成本、改善供應鏈以及採用社區為基礎的分銷策略。
• 與公共衛生計劃的整合：瘧疾疫苗擴大被納入更廣泛的公共衛生計劃，包括針對其他媒介傳播疾病的計劃。這種方法背離了將疫苗接種作為針對瘧疾的臨時行動的傳統觀點。在這種情況下，這樣的策略將在整體瘧疾控制計畫中使用疫苗，其中包括病媒控制措施、教育宣傳活動等以及醫療保健基礎設施的改善。為了最大限度地提高瘧疾疫苗宣傳活動的有效性，需要採取這種綜合努力。
• 疫苗輸送的進步：無針注射和耐熱配方等疫苗輸送技術的創新正在成為市場的主要趨勢。這些進展對於促進疫苗的接種非常重要，特別是在偏遠和資源匱乏的地區。它還有助於限制後勤複雜性，同時確保疫苗有針對性地交付給迫切需要疫苗的貧困社區。

透過技術創新、全球合作和提高疫苗供應，這些新趨勢正在重塑瘧疾疫苗市場。這些趨勢對於實現全球瘧疾控制和根除目標的重要性怎麼強調也不為過。

瘧疾疫苗市場的最新趨勢

瘧疾疫苗市場正在經歷各種重大變化，對產業產生重大影響。這些變化是由技術進步、全球合作以及消除流行地區瘧疾的需要所推動的。以下是市場上一些最重要的最新發展。

• 世界衛生組織對新疫苗核准：世界衛生組織（WHO）最近對新的瘧疾疫苗進行了資格預審，標誌著其在全球推廣的重要一步。此認證確保該疫苗符合全球公認的安全性和效率要求，並允許其用於大規模免疫工作。這項變化的幅度是巨大的，因為它將加快瘧疾流行地區獲得疫苗的速度。
• 基於 mRNA 的瘧疾疫苗的進展：mRNA 技術在 COVID-19 疫苗接種中的成功推動了基於 mRNA 的瘧疾疫苗的開發。這些疫苗目前正在臨床試驗中進行評估，初步資料有希望。這項開發的潛在價值是巨大的，因為 mRNA 疫苗有可能比傳統疫苗生產方法表現出更高的有效率並且生產速度更快。
• 擴大疫苗生產能力：最近為擴大疫苗生產能力而進行的投資，特別是在非洲，正在改變瘧疾疫苗市場。這些發展包括建立新的製造設施以及與當地製造商合作。這項發展的重要性怎麼強調都不為過。這對於透過提高疫苗供應量和減少對進口的依賴來提高區域疫苗供應自給自足至關重要。
• 推出多系統疫苗：推出針對多種瘧疾原蟲的疫苗是市場的重要發展。這些疫苗旨在提供更廣泛的保護並降低抗藥性風險。這具有重大意義，因為它解決了寄生蟲多樣性問題並提高了瘧疾疫苗接種計劃的整體有效性。
• 為瘧疾疫苗研究提供更多資金：政府、非政府組織和私人企業的投資正在迅速增加全球瘧疾疫苗研究的資金，加速疫苗開發。資金的增加不僅為擴大臨床試驗創造了空間，而且還為探索新的候選疫苗和開發多種技術創造了空間。在瘧疾疫苗市場，資金的增加正在導致快速進步和管道擴張。

上述幾點引發了瘧疾疫苗產業的重大變革，增加了有效預防和控制瘧疾的潛力。這些進步將提供更有效、更容易取得的疫苗選擇，並有助於全球採用瘧疾疫苗。

瘧疾疫苗市場的策略性成長機會

瘧疾疫苗市場擁有眾多策略性成長機會，特別是公共衛生計畫、疫苗開拓和技術進步等關鍵應用。這些可能性歸因於兩個主要因素：解決瘧疾流行地區問題的迫切需求以及增加全球疫苗覆蓋率的機會。以下我們將介紹業務拓展的主要領域。

• 擴展到公共衛生計劃瘧疾疫苗接種的公共衛生計劃為顯著成長和發展提供了途徑。政府和組織可以利用疫苗，將其納入更廣泛的衛生活動，包括對抗其他感染疾病。這種方法使瘧疾疫苗能夠惠及盡可能多的人，同時也是瘧疾綜合控制策略的一部分。
• 兒科疫苗開發：為弱勢兒童生產具有適合年齡的配方和給藥方案的瘧疾疫苗是該市場最重要的成長機會之一。為了降低瘧疾造成的兒童死亡率，需要製定適合年齡的兒童免疫接種，並採用適當的配方和給藥方案。由於兒科疫苗在疾病高發生率地區的重要性，預計對兒科疫苗的關注將推動市場的顯著成長。
• 聯合免疫的進展：針對包括瘧疾在內的多種疾病的聯合疫苗具有策略性成長的潛力。這些疫苗接種可以簡化免疫計劃並提高免疫率，特別是在資源有限的環境中。鑑於其成本效益，組合疫苗有望廣泛使用，因為它們擴大了免疫規劃並減輕了多種感染疾病的負擔。
• 提高生產能力：投資擴大疫苗生產能力，特別是在瘧疾流行地區，可以帶來巨大的成長機會。透過開發本地生產設施並與區域製造商合作，公司可以增加疫苗的供應量，同時減少對進口的依賴。這不僅改善了疫苗的獲取，也促進了地方經濟的發展。
• 專注於創新：持續關注基於 mRNA 的瘧疾疫苗等創新將成為成長的主要動力。此類技術可以幫助提高疫苗有效性、降低製造成本並加快向受災者分發疫苗。一旦這些新技術被開發出來並商業化，預計市場將出現顯著成長。

瘧疾疫苗市場正在因某些策略性成長機會而發生轉變，這些機會旨在鼓勵發明、改善可及性以及將疫苗與更全面的醫療保健計劃相結合。這種潛力將被各種公司和政府機構利用，促進市場的顯著成長，從而推動全球消除瘧疾的努力。

瘧疾疫苗市場推廣因素及挑戰

瘧疾疫苗市場受到技術進步、經濟狀況、監管原則等一系列因素的影響。了解這些力量有助於公司在市場上成功運作。因此，本演講總結了影響市場的主要促進因素和挑戰。

推動瘧疾疫苗市場的因素是：

1.技術進步：瘧疾疫苗市場是由技術進步驅動的，例如基於mRNA的平台和新型佐劑的使用。這些因素為開發更好的疫苗提供了空間，並為開發針對不斷變化的瘧疾原蟲更有效、更適應的疫苗提供了機會。這些技術變革至關重要，因為它們將提高疫苗的效率並增加全球消滅瘧疾的機會。

2. 全球衛生計劃：世界衛生組織、聯合國兒童基金會和比爾及梅琳達蓋茲基金會主導的全球健康計劃正在推動瘧疾疫苗市場的擴張。這些組織為疫苗開發、研發和分銷網路提供必要的資金、研究支援和供應鏈。其結果是在瘧疾高發生地區更快獲得疫苗，支持全球消除瘧疾的努力。

3.增加資金籌措：瘧疾疫苗的開發和研究隨著全球資金的增加而不斷成長，是市場成長的基礎。我們支持探索新的候選疫苗，擴大臨床試驗，並透過政府、非政府組織 (NGO) 和私營部門的特定投資資金籌措來建立生產能力。高資金籌措水準也有助於瘧疾疫苗市場的快速發展和廣泛的產品研發。

4. 疾病負擔日益加重：在撒哈拉以南非洲國家和亞洲部分地區，仍有大量人口患有瘧疾，因此需要更好的疫苗。這些努力是由降低瘧疾發病率和死亡率（主要是兒童和孕婦）的更廣泛需求所推動的。疾病負擔日益增加的重大影響凸顯了全球瘧疾控制的迫切性。

5.政府支持：推動該市場銷售的主要因素是政府對消除瘧疾的大力支持以及將疫苗納入國家免疫規劃。在大多數情況下，流行地區政府越來越重視將疫苗接種策略納入更廣泛的公共衛生框架。政府的支持使得大規模的免疫工作得以進行，同時維持了對疫苗的需求。

瘧疾疫苗市場的挑戰包括：

1. 監管障礙：應對複雜的法規環境是瘧疾疫苗市場的重大挑戰。新疫苗技術必須滿足嚴格的安全性和有效性標準，這可能會減慢核准和分發過程。監管障礙的影響很大，因為它們阻礙了最需要疫苗的地區獲得疫苗。

2. 製造成本高：製造複雜的瘧疾疫苗，特別是採用新技術的疫苗，高成本，限制了該產業的擴張。這些成本可能使它們難以承受且難以獲得，特別是對於低收入群體而言。高製造成本的影響是巨大的，限制了疫苗接種計劃的覆蓋範圍，並減緩了國際上消除瘧疾的進展。

3. 供應鏈限制：在瘧疾流行地區，供應鏈基礎設施薄弱限制了疫苗的供應和使用。只有當疫苗到達偏遠和資源匱乏地區時，免疫宣傳活動才能成功。供應鏈限制的影響是巨大的，因為它們會導致疫苗推出的延遲，並破壞有效控制瘧疾的努力。

瘧疾疫苗市場的主要促進因素和挑戰將塑造瘧疾預防和控制的未來。儘管市場成長是由技術進步和資金籌措增加所推動的，但也存在明顯的障礙，例如監管限制、高製造成本和供應鏈限制。這些都是瘧疾疫苗市場持續發展需要平衡的因素，有助於實現消滅瘧疾的全球目標。

瘧疾疫苗細分市場

這項研究按類型、藥物、最終用途和地區對全球瘧疾疫苗進行了預測。

各國瘧疾疫苗市場前景

由於研究開拓、研究經費增加以及控制流行地區瘧疾的需要，瘧疾疫苗市場正在經歷重大發展。這些發展由德國、印度、美國、中國和日本等主要市場主導，每個市場對全球努力的貢獻都不同。新興國家的近期趨勢如下。

• 美國：瘧疾疫苗研究的資金正在增加，包括比爾及梅琳達蓋茲基金會和美國國立衛生研究院在內的各種組織都發揮關鍵作用。迄今為止的進展包括下一代瘧疾疫苗臨床試驗的進展，重點是提高其功效並擴大針對多種瘧疾菌株的覆蓋範圍。此外，美國在開發新佐劑以提高疫苗效率方面發揮主導作用。
• 透過與非洲國家的合作，中國在瘧疾疫苗研發領域取得了重大進展。這也包括里程碑，例如本地生產的疫苗的後期臨床試驗。中國的「一帶一路」計劃還可以在全部區域分發這些疫苗，使其成為一項致力於降低瘧疾相關發病率和死亡率的全球衛生舉措，這證明了中國作為合作夥伴的重要性。
• 德國 德國與國際組織和非洲研究中心在瘧疾疫苗研究的合作是最新進展之一。我們支持不同的疫苗來應對引起瘧疾的寄生蟲生命週期的不同階段。根據對健康和疾病控制的全球承諾，德國的目標是使這些疫苗具有可擴展性和可負擔性，以便在全球廣泛使用。
• 印度 印度在瘧疾藥物領域取得了重大進展，並取得了多項進展，包括在該國開始本土疫苗的臨床試驗。與印度政府合作的全球衛生組織也致力於向高流行地區分發疫苗。這顯示印度正在努力實現無瘧疾社會，並已成為全球疫苗市場的關鍵參與者。
• 日本 日本憑藉其先進的生物技術部門，在瘧疾疫苗研究中發揮重要作用。最近的進展包括日本和非洲科學家共同進行的臨床試驗以及針對亞洲和非洲流行的特定瘧疾菌株的疫苗的開發。為了實現全球熱帶醫學目標，日本研究人員的貢獻是提高整體疫苗效率並擴大世界各地瘧疾流行地區獲得瘧疾預防措施的機會。

常問問題

Q.1 瘧疾疫苗的市場規模有多大？

A1. 到 2030 年，全球瘧疾疫苗市場預計將達到 69 億美元。

Q.2 瘧疾疫苗市場的成長預測如何？

A2. 2024年至2030年，全球瘧疾疫苗市場預計將以18.6%的複合年成長率成長。

Q.3 影響瘧疾疫苗市場成長的關鍵促進因素有哪些？

A3. 該市場的主要驅動力是對瘧疾疫苗的需求不斷成長、前紅系疫苗的出現以及對疫苗輸送平台的日益偏好。

Q4.市場的主要細分市場是：

A4. 瘧疾疫苗市場前景廣闊，醫院、專科診所和居家醫療市場都有機會。

Q5.市場的主要企業是：

A5. 主要瘧疾疫苗公司如下：

• Actiza Pharmaceutical
• AdvaCare Pharma
• Ipca Laboratories
• Bliss GVS Pharma
• GeoVax
• Sumaya Biotech
• VLP Therapeutics
• OSIVAX
• AJANTA PHARMA
• Strides Pharma Science

Q6.未來最大的細分市場是什麼？

A6.Lucintel 預測，前紅血球在預測期內將經歷最高的成長。

Q7. 未來五年預計哪些地區的市場成長最大？

A7. 由於其強大的醫療基礎設施、對疫苗研發的高投資以及主要製造商的存在，北美將繼續成為最大的地區。

Q8. 可以客製化報告嗎？

A8. 是的，Lucintel 提供 10% 的客製化服務，無需額外付費。

目錄

第1章執行摘要

第2章全球瘧疾疫苗市場：市場動態

• 簡介、背景、分類
• 供應鏈
• 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

• 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
• 全球瘧疾疫苗市場趨勢（2018-2023）與預測（2024-2030）
• 全球瘧疾疫苗市場，依類型
  • 紅系前期
  • 紅血球
  • 多抗原
  • 其他
• 全球瘧疾疫苗市場（按藥物）
  • 瘧疾原蟲
  • 瘧疾原蟲
  • 依蚊
• 全球瘧疾疫苗市場（依最終用途）
  • 醫院
  • 專科診所
  • 居家護理
  • 其他

第4章 2018-2030年區域市場趨勢及預測分析

• 全球瘧疾疫苗市場（按地區）
• 北美瘧疾疫苗市場
• 歐洲瘧疾疫苗市場
• 亞太瘧疾疫苗市場
• 其他區域瘧疾疫苗市場

第5章 競爭分析

• 產品系列分析
• 業務整合
• 波特五力分析

第6章 成長機會與策略分析

• 成長機會分析
  • 全球瘧疾疫苗市場的成長機會（按類型）
  • 全球瘧疾疫苗市場的成長機會（按藥物）
  • 全球瘧疾疫苗市場成長機會（依最終用途）
  • 全球瘧疾疫苗市場成長機會（按地區）
• 全球瘧疾疫苗市場的新趨勢
• 戰略分析
  • 新產品開發
  • 擴大全球瘧疾疫苗市場產能
  • 全球瘧疾疫苗市場的合併、收購和合資企業
  • 認證和許可

第7章主要企業概況

• Actiza Pharmaceutical
• AdvaCare Pharma
  • Ipca Laboratories
• Bliss GVS Pharma
• GeoVax
• Sumaya Biotech
• VLP Therapeutics
• OSIVAX
• AJANTA PHARMA
• Strides Pharma Science

Malaria Vaccine Trends and Forecast

The future of the global malaria vaccine market looks promising with opportunities in the hospital, specialty clinic, and homecare markets. The global malaria vaccine market is expected to reach an estimated $6.9 billion by 2030 with a CAGR of 18.6% from 2024 to 2030. The major drivers for this market are growing demand for malaria vaccines, emergence of pre-erythrocytic vaccines, and rising preference for vaccine delivery platforms.

Lucintel forecasts that pre-erythrocytic is expected to witness highest growth over the forecast period.

Within this market, hospital is expected to witness highest growth over the forecast period.

North America will remain the largest region due to existence of robust healthcare infrastructure, high investment in vaccines research and development, and presence of key manufacturers in the region.

Emerging Trends in the Malaria Vaccine Market

There are several emerging trends that are shaping the future of malaria prevention and control in the malaria vaccine market. These trends arise from technological progress, increased global cooperation, and higher emphasis on public health. The following summaries provide an overview of major drivers affecting the market.

• Increased Global Collaboration: International partnerships have become more frequent allowing for the exchange of research, resources, and know-how across countries. This trend is leading to the development of more effective and accessible malaria vaccines. Collaboration between developed and developing nations is particularly important in addressing unique challenges faced by malaria endemic zones leading to more focused and sustainable vaccine solutions.
• Next-Generation Vaccines: A lot of research now focuses on next-generation malaria vaccines that can broadly protect against several strains of the parasite. These vaccines aim to address the limitations afflicting current vaccines such as low efficacy or strain-specific protection. This trend is very vital for the long-term control and eradication of malaria since it accounts for changes like the malaria parasite over time as well as its resistance to available drugs.
• The Focus on Vaccine Accessibility: There is a growing push to ensure malaria vaccines are effective and affordable to populations in endemic regions. The trend reflects the realization that addressing vaccine distribution challenges is important to achieve global malaria elimination targets. This encompasses reducing production costs, improving supply chains, and adopting community-based distribution strategies.
• Integration with Public Health Programs: Malaria vaccines are increasingly being integrated into broader public health programs, including those targeting other vector-borne diseases. This approach is a departure from traditional thinking which sees vaccination as a perfunctory action against malaria. In this case, such a strategy involves the use of vaccines alongside vector control measures and educational campaigns among others within an overall plan for fighting malaria that may also include improved healthcare infrastructure. These integration efforts are necessary to maximize the impact of malaria vaccination campaigns.
• Advancements in Vaccine Delivery: Innovations in vaccine delivery technologies like needle-free injections and thermostable formulations are emerging as key trends in the market. These developments have notable importance for enhancing the uptake of vaccines, particularly in remote areas and resource-poor settings. Furthermore, they help curb logistical complexity while ensuring targeted delivery to needy societies that require vaccines urgently.

By increasing innovation, global cooperation, and accessibility of vaccines, these emerging trends are reshaping the malaria vaccine market. The importance of these trends in achieving global malaria control and eradication goals cannot be overstated.

Recent Developments in the Malaria Vaccine Market

The malaria vaccine market is undergoing various significant changes that have impacted the industry greatly. These developments are driven by technological advancements, global collaborations, and the need to control malaria in endemic areas. Here are some of the most important recent developments in the market.

• WHO Prequalification of New Vaccines: The World Health Organization (WHO) recently pre-qualified new malaria vaccines, representing an important stage in their global deployment. This qualification ensures that the vaccines satisfy globally accepted safety and efficiency requirements so that they can be used in large-scale immunization initiatives. The magnitude of this change is immense since it hastens access to vaccines within malaria-endemic regions.
• Advancement of mRNA-based Malaria Vaccines: The development of mRNA-based malaria vaccines has been buoyed by the success of mRNA technologies in COVID-19 vaccinations. Currently, these vaccines are being evaluated through clinical trials and have early data showing promise. The potential value of this development is substantial because mRNA vaccines may offer higher efficacy rates and be manufactured faster than traditional vaccine methods.
• Expanding Vaccine Manufacturing Capabilities: Recent investments in expanding vaccine manufacturing capabilities, particularly in Africa, are transforming the malaria vaccine market. Such developments include setting up new production facilities and partnering with local manufacturers. The importance of this development cannot be overemphasized as it is critical for improving vaccine availability and reducing dependency on importations, thus enhancing regional self-sufficiency in vaccine supply.
• Introduction of Multi-Strain Vaccines: The introduction of vaccines that target multiple strains of the malaria parasite is a key development in the market. These vaccines aim to provide broader protection and reduce the risk of resistance. This has had a significant impact because it addresses the problem of parasite diversity and improves the overall efficacy of malaria vaccination programs.
• More Funding for Malaria Vaccine Research: The worldwide surge in funding for malaria vaccine research led by governments, NGOs, and private sector investments is speeding up vaccine development. With these increased resources, there has been room to explore new candidates for vaccines as well as develop diverse technologies besides broadening clinical trials. An enlarged fraction of funds has led to rapid advancements as well as pipeline expansion experienced in the market for malaria vaccines.

The above-mentioned points are catalysts for major transformations in the malaria vaccine industry, thereby enhancing the potential for effective malaria prevention and management. These advancements will likely result in stronger and more accessible vaccine options, thus contributing to the global campa

Strategic Growth Opportunities for Malaria Vaccine Market

There are numerous strategic opportunities for growth in the malaria vaccine market, especially about key applications like public health programs, vaccine development, and technological advancements. These possibilities are caused by two main factors: the pressing need to address malaria endemic areas and a chance to increase global coverage of vaccines. The next summaries highlight major areas for business expansion.

• Expanding into Public Health Programs: Public health programs in malaria vaccination will provide an avenue for tremendous growth and development. Governments and organizations can make use of their vaccines by integrating them into wider health initiatives such as those that address other infectious diseases. This approach helps ensure that malaria vaccines reach as many people as possible while also making sure that they form part of a comprehensive malaria-fighting strategy.
• Development of Pediatric Vaccines: Producing age-appropriate formulations and dosage schedules of malaria vaccines for vulnerable children represents one of the most important opportunities for growth in this market. To lower child mortality rates due to malaria, age-specific pediatric immunizations should be developed with appropriate formulations and dosing schedules. By focusing on pediatric vaccines, it is expected that there will be significant market growth since this particular demographic is important in areas where there is a high prevalence rate of the disease.
• Progress in Combination Immunization: Combination vaccines that target multiple diseases, including malaria, have the potential for strategic growth. These shots streamline immunization schedules and enhance vaccination coverage, particularly in resource-limited settings. Given their cost-effectiveness, combination vaccines are expected to gain traction as they expand immunization programs and reduce the burden of multiple infectious diseases.
• Manufacturing Capacity Increase: One can find a vital growth opportunity in investing in vaccine manufacturing capacity expansion, particularly in malaria-endemic areas. Through developing local production facilities and partnering with regional manufacturers, firms can increase vaccine availability while reducing reliance on imports. This way improves not only vaccine access but also encourages economic development at a local level.
• Technological Innovation Focus: The continued emphasis on technological innovation such as mRNA-based malaria vaccines is a major driver for growth. Such technologies will help enhance vaccine efficacy, lower production expenses, and speed up the distribution of vaccines to suffering populations. Massive market growth is expected when these new technologies are developed and commercialized.

The malaria vaccine market is being transformed by certain strategic growth opportunities, which are aimed at encouraging invention, increasing access, and merging vaccines with more comprehensive healthcare schemes. Such possibilities will be exploited by various businesses and governmental organizations, thus fostering a notable increase in the market boosting worldwide efforts towards eliminating malaria.

Malaria Vaccine Market Driver and Challenges

The market for malaria vaccine is influenced by a series of factors such as technological progress, economic terms, and regulatory principles. Knowing these forces will help a firm to operate well in the market. Therefore, this presentation gives summaries of the main drivers and challenges that affect the market.

The factors responsible for driving the malaria vaccine market include:

1. Technological Advancements: The malaria vaccine market is driven by technological advancements such as the use of mRNA-based platforms and novel adjuvants. These factors give room for better vaccines and offer opportunities for the development of more effective, adaptable vaccines against changing malaria parasites. The impact of these technological changes is critical since they boost vaccine efficiency and increase chances for global malaria elimination.

2. Global Health Initiatives: The expansion of the malaria vaccine market is being pushed by international health initiatives led by WHO, UNICEF, Bill & Melinda Gates Foundation. These organizations provide crucial funding, research assistance, and supply chains for vaccine discovery, development, and distribution networks that are integral to this process. This results in faster access to vaccines in regions with high rates of malaria; thus supporting global efforts towards eradicating malaria in the world.

3. Increased Funding: Malaria vaccine development and research, which is globally funded and has grown, forms the basis of market growth. It supports the search for new vaccine candidates, expansion of clinical trials, and capacity building for production through fundraising by governments, nongovernmental organizations (NGOs), and private sector investments. The high funding levels also contribute to rapid developments as well as a broader pipeline in the malaria vaccine market.

4. Rising Disease Burden: Among others in sub-Saharan Africa and certain Asian countries, there are still large numbers of people suffering from malaria and this is a reason why they seek good vaccines. These efforts are driven by the widespread need to reduce malaria-related morbidity and mortality experienced mainly among children and pregnant women. The significant impact of increasing disease burden emphasizes urgency towards global malaria control.

5. Government Support: The main factor driving sales in this market is strong government support to achieve the elimination of malaria as well as the integration of vaccines into national immunization programs. In most cases, governments in endemic areas have increased their focus on vaccination strategies to be integrated within wider public health frameworks. Governments' support ensures that large-scale immunization efforts can occur while keeping up demand for vaccines being met.,

Challenges in the malaria vaccine market are:

1. Regulatory Hurdles: For the malaria vaccine market, navigating intricate regulatory environments is a significant challenge. Stringent safety and efficacy standards have to be met for new vaccine technologies, which can slow down approval and distribution processes. The impact of regulatory hurdles is great as they hinder the accessibility of vaccines in areas where they are needed most.

2. High Production Costs: The high costs associated with manufacturing sophisticated malaria vaccines, especially those that incorporate novel technologies, limit the expansion of the industry. The expenses can make them unaffordable and inaccessible, particularly in low-income areas. The impact of high production costs is significant as it restricts vaccination programs' coverage and slows international progress toward the elimination of malaria.

3. Supply Chain Limitations: Poor supply chain infrastructure in regions with endemic malaria restricts the availability and utilization of vaccines. Immunization campaigns can only succeed if vaccines reach remote and resource-poor places. The effect of supply chain limitations is considerable because it causes delays in vaccine rollouts and undermines efforts to control malaria effectively.

The major drivers and challenges in the malaria vaccine market are shaping the future of malaria prevention and control. Market growth is driven by technological advancements as well as increased funding; however, there are notable obstacles including regulatory restrictions, high production costs, and supply chain constraints. Those are the factors that need to be balanced for continuous progress of the malaria vaccine market which could help in reaching global goals for malaria eradication.

List of Malaria Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies malaria vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the malaria vaccine companies profiled in this report include-

• Actiza Pharmaceutical
• AdvaCare Pharma
• Ipca Laboratories
• Bliss GVS Pharma
• GeoVax
• Sumaya Biotech
• VLP Therapeutics
• OSIVAX
• AJANTA PHARMA
• Strides Pharma Science

Malaria Vaccine by Segment

The study includes a forecast for the global malaria vaccine by type, agent, end use, and region.

Malaria Vaccine Market by Type [Analysis by Value from 2018 to 2030]:

• Pre-Erythrocytic
• Erythrocytic
• Multi-Antigen
• Others

Malaria Vaccine Market by Agent [Analysis by Value from 2018 to 2030]:

• Plasmodium Falciparum
• Plasmodium Vivax
• Anopheles Species

Malaria Vaccine Market by End Use [Analysis by Value from 2018 to 2030]:

• Hospitals
• Specialty Clinics
• Homecare
• Others

Malaria Vaccine Market by Region [Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Malaria Vaccine Market

Advances in research, increased funding, and the need to combat malaria in endemic areas have resulted in considerable development of the malaria vaccine market. These developments are being led by key markets including Germany, India, the United States, China, and Japan which each contribute differently toward the global effort. The summaries below provide insights into recent developments within these countries.

• United States: Funding for malaria vaccine research has increased with various organizations such as Bill & Melinda Gates Foundation and NIH playing a major role. Progress made so far includes advancements made in clinical trials for next-generation malaria vaccines that focused on improving their efficacy and providing broader coverage against multiple strains of malaria. Additionally, the USA is leading in new adjuvant development to enhance vaccine efficiency.
• China: In collaboration with African countries, China has advanced significantly in the field of developing a vaccination against malaria. These include milestones like late-stage clinical trials of locally produced vaccines. China's Belt and Road Initiative also makes available these vaccines for distribution across malaria-endemic regions thus illustrating its significance as a partner in global health initiatives emphasizing reduction of malaria-related morbidity and mortality rates.
• Germany: The collaboration of Germany with international bodies and African research centers on malaria vaccine research is one of the recent developments. They have supported different vaccines to deal with various stages in the life cycle of a parasite causing malaria. It aims to make these vaccines scalable and affordable so that they can be widely used globally in line with its worldwide commitment to health and disease control.
• India: India has made remarkable progress in the area of malaria drugs with some strides such as; launching clinical trials for native vaccines within her territory. Global health organizations partnering with the Indian government are also emphasizing the distribution of vaccines across high-endemic areas. This demonstrates how India is working towards attaining a malaria-free society, thus making it an important player in the global vaccine market.
• Japan: Japan plays a vital role in research on malaria vaccines through its advanced biotechnology sector. Some recent developments include clinical trials conducted together by Japanese scientists and their African counterparts as well as the development of specific vaccines targeting particular strains of malaria prevalent in Asia and Africa. Achieving global tropical medicine objectives, Japanese researchers' contribution consists of increasing overall vaccine efficiency as well as enlarging accessibility to preventive measures against malaria among infected regions worldwide.

Features of the Global Malaria Vaccine Market

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Malaria vaccine market size by type, agent, end use, and region in terms of value ($B).

Regional Analysis: Malaria vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, agents, end uses, and regions for the malaria vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the malaria vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

FAQ

Q.1 What is the malaria vaccine market size?

Answer: The global malaria vaccine market is expected to reach an estimated $6.9 billion by 2030.

Q.2 What is the growth forecast for malaria vaccine market?

Answer: The global malaria vaccine market is expected to grow with a CAGR of 18.6% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the malaria vaccine market?

Answer: The major drivers for this market are growing demand for malaria vaccines, emergence of pre-erythrocytic vaccines, and rising preference for vaccine delivery platforms.

Q4. What are the major segments for malaria vaccine market?

Answer: The future of the malaria vaccine market looks promising with opportunities in the hospital, specialty clinic, and homecare markets.

Q5. Who are the key malaria vaccine market companies?

Answer: Some of the key malaria vaccine companies are as follows:

• Actiza Pharmaceutical
• AdvaCare Pharma
• Ipca Laboratories
• Bliss GVS Pharma
• GeoVax
• Sumaya Biotech
• VLP Therapeutics
• OSIVAX
• AJANTA PHARMA
• Strides Pharma Science

Q6. Which malaria vaccine market segment will be the largest in future?

Answer: Lucintel forecasts that pre-erythrocytic is expected to witness highest growth over the forecast period.

Q7. In malaria vaccine market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region due to existence of robust healthcare infrastructure, high investment in vaccines research and development, and presence of key manufacturers in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the malaria vaccine market by type (pre-erythrocytic, erythrocytic, multi-antigen, and others), agent (plasmodium falciparum, plasmodium vivax, and anopheles species), end use (hospitals, specialty clinics, homecare, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Malaria Vaccine Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Malaria Vaccine Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Malaria Vaccine Market by Type
  • 3.3.1: Pre-Erythrocytic
  • 3.3.2: Erythrocytic
  • 3.3.3: Multi-Antigen
  • 3.3.4: Others
• 3.4: Global Malaria Vaccine Market by Agent
  • 3.4.1: Plasmodium Falciparum
  • 3.4.2: Plasmodium Vivax
  • 3.4.3: Anopheles Species
• 3.5: Global Malaria Vaccine Market by End Use
  • 3.5.1: Hospitals
  • 3.5.2: Specialty Clinics
  • 3.5.3: Homecare
  • 3.5.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Malaria Vaccine Market by Region
• 4.2: North American Malaria Vaccine Market
  • 4.2.1: North American Malaria Vaccine Market by Type: Pre-Erythrocytic, Erythrocytic, Multi-Antigen, and Others
  • 4.2.2: North American Malaria Vaccine Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
• 4.3: European Malaria Vaccine Market
  • 4.3.1: European Malaria Vaccine Market by Type: Pre-Erythrocytic, Erythrocytic, Multi-Antigen, and Others
  • 4.3.2: European Malaria Vaccine Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
• 4.4: APAC Malaria Vaccine Market
  • 4.4.1: APAC Malaria Vaccine Market by Type: Pre-Erythrocytic, Erythrocytic, Multi-Antigen, and Others
  • 4.4.2: APAC Malaria Vaccine Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
• 4.5: ROW Malaria Vaccine Market
  • 4.5.1: ROW Malaria Vaccine Market by Type: Pre-Erythrocytic, Erythrocytic, Multi-Antigen, and Others
  • 4.5.2: ROW Malaria Vaccine Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Malaria Vaccine Market by Type
  • 6.1.2: Growth Opportunities for the Global Malaria Vaccine Market by Agent
  • 6.1.3: Growth Opportunities for the Global Malaria Vaccine Market by End Use
  • 6.1.4: Growth Opportunities for the Global Malaria Vaccine Market by Region
• 6.2: Emerging Trends in the Global Malaria Vaccine Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Malaria Vaccine Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Malaria Vaccine Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Actiza Pharmaceutical
• 7.2: AdvaCare Pharma
  • 7.1.1: Ipca Laboratories
• 7.4: Bliss GVS Pharma
• 7.5: GeoVax
• 7.6: Sumaya Biotech
• 7.7: VLP Therapeutics
• 7.8: OSIVAX
• 7.9: AJANTA PHARMA
• 7.10: Strides Pharma Science